Carbyne partners with ambitious founders and management teams to build successful and long-lasting businesses
Carbyne Equity Partners is a private equity firm that invests in growing European businesses with strong market positions. Founded in 2023, Carbyne is headquartered in Hamburg, Germany
Carbyne is agile
We operate fast and with precision, supported by a streamlined, one-tier investment committee that enables us to meet competitive timelines. When needed, we can leverage bridge financing for debt components to maintain momentum. Our single-LP structure, combined with a broad mandate, gives us the flexibility to adapt quickly to emerging opportunities and shifting market dynamics.
Carbyne is entrepreneurial
The team combines operational experience with strong deal-making capabilities, making Carbyne a trusted partner for entrepreneurs and management teams ready to take their business to the next level. We bring firsthand industry expertise and an extensive network to support growth and expansion.
Carbyne is a good home
By combining a professional PE structure with the values and expertise of a renowned family business, Carbyne is positioned as a good home for companies and their management teams — including the option to become a permanent part of the LP’s family enterprise.
We have partnered with a German entrepreneurial family to set up Carbyne. The family’s core activities are R&D driven, have a global footprint, and are clustered around genetics, -health and -nutrition as well as diagnostics.
As sector specialists, we focus on:
We invest in innovative sectors shaping the future of healthcare and technology. Our priorities include:
Life Science Services: Driving better patient outcomes through Clinical Research Organizations (CRO), medical affairs, and pharmacovigilance expertise.
MedTech: Advancing care with surgical robotics, dental solutions, cardiovascular technologies, minimally invasive procedures, digital diagnostics, and hospital facility software.
Emerging Opportunities: Supporting late-stage biotech breakthroughs, ESG reporting services, and secure radioisotope supply for critical applications.
We partner with innovators delivering high-quality ingredients and solutions that power everyday products. Our focus includes Food & Beverage, Consumer Health, Beauty & Personal Care, Home Essentials, and Pet & Animal Nutrition:
Manufacturers and Formulators: Developing and producing functional and nutritional specialty ingredients.
Distributors: Trusted partners ensuring efficient global supply chains for specialty ingredients, connecting manufacturers with brands.
Ancillary Services: Providers of quality assurance solutions, and reporting services that enable compliance, sustainability, and innovation across the value chain.
We invest in solutions that drive sustainable farming and improve crop efficiency. Our priorities include:
Biologic Crop Protection and Nutrition: Advancing eco-friendly biologic crop protection and nutrition technologies that reduce chemical dependency and enhance soil health.
Farm Technology & Precision Farming: Supporting innovations in smart farming tools, data-driven crop management, and automation to optimize yields and resource efficiency.
Agricultural CROs: Partnering with research organizations that deliver testing, trials, and regulatory expertise for next-generation agricultural products.
| for Buyouts | for Growth Equity | |
|---|---|---|
| Equity tickets | Up to € 150m | Up to € 50m |
| Situations | MBO, MBI, secondaries, carve-outs, successions, growth | Growth |
| Geography | Platform investments must be in Europe, add-ons can be worldwide | Europe |
| Profitability | Minimum average profitability, no turnarounds | Profitability within two years expected |
| Growth | Above average growth | Strong growth |
| Control | Preferably majority stakes with management participation. Minority stakes only if the path for a 100% exit is defined | Majority and minority stakes |